Topline data from confirmatory Launch-HTN trial expected in 2H 2025
Topline data from ongoing Advance-HTN pivotal trial expected in 2H 2024
RADNOR, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by abnormally elevated aldosterone, today announced that the first subject has been dosed in the Launch-HTN (NCT06153693) pivotal trial to evaluate the safety and efficacy of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN), when used as an add-on therapy to prescribed background treatment.
Initiating this second pivotal trial demonstrates the continued progress were making towards introducing a targeted approach to care in hypertension by identifying and profiling potential responders to lorundrostat, stated Jon Congleton, Chief Executive Officer of Mineralys. In parallel with our development of lorundrostat, we have been pleased to see accumulating evidence generated by the medical community highlighting aldosterone as a key driver in cardiorenal disease.
Launch-HTN is the second of two clinical trials under the planned pivotal program to evaluate the safety and efficacy of lorundrostat when added to subjects existing background hypertension treatment. This trial is designed to model real world treatment of uHTN and rHTN in the primary care setting. Launch-HTN is a global, randomized, double-blinded, placebo-controlled Phase 3 trial that is designed to enroll up to approximately 1,000 eligible adult participants who are failing to achieve their blood pressure goal on two to five background antihypertensive medications. Eligible subjects will be randomized to one of three arms: placebo, lorundrostat 50 mg once daily (QD), and lorundrostat 50 mg QD and then titrated to 100 mg QD, as needed, at week six. The primary endpoint of the trial is change from baseline in systolic blood pressure versus placebo after 12 weeks of treatment, as measured by automated office blood pressure monitoring.
Previously, in May 2023, the Company announced the first subject dosed in the first pivotal trial, Advance-HTN. The Company expects to announce topline data from the Advance-HTN trial in the second half of 2024. Subjects in both the Advance-HTN and Launch-HTN trials are provided the opportunity to participate in the open-label extension trial, Transform-HTN.
About Hypertension Having sustained, elevated blood pressure (or hypertension) increases the risk of heart disease, heart attack and stroke, which are leading causes of death in the U.S. In 2020, more than 670,000 deaths in the U.S. included hypertension as a primary or contributing cause. Hypertension and related health issues resulted in an average annual economic burden of about $130 billion each year in the U.S., averaged over 12 years from 2003 to 2014.
Less than 50% of hypertension patients achieve their blood pressure goal with currently available medications. Abnormally elevated aldosterone levels are a key factor in driving hypertension in approximately 25% of all hypertensive patients.
About Lorundrostat Lorundrostat is a proprietary, orally administered, highly selective aldosterone synthase inhibitor being developed for the treatment of uncontrolled and resistant hypertension and CKD. Lorundrostat was designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for its production. Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, an observed half-life of 10-12 hours and demonstrated approximately a 70% reduction in plasma aldosterone concentration in hypertensive subjects.
About Mineralys Therapeutics Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by abnormally elevated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Forward-Looking Statements Mineralys Therapeutics cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding: the potential therapeutic benefits of lorundrostat; the Companys expectation that aldosterone synthase inhibitors with an SGLT2 inhibitor may provide additive clinical benefits to patients; the Companys expectation that the Advance-HTN and the planned Phase 3 clinical trial of lorundrostat may serve as pivotal trials in any submission of a new drug application (NDA) to the United States Food and Drug Administration (FDA); the Companys ability to evaluate lorundrostat as a potential treatment for CKD or uncontrolled hypertension; the planned future clinical development of lorundrostat and the timing thereof; and the expected timing of commencement and enrollment of patients in clinical trials and topline results from clinical trials. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future performance is dependent entirely on the success of lorundrostat; potential delays in the commencement, enrollment and completion of clinical trials and nonclinical studies; later developments with the FDA may be inconsistent with the feedback from the completed end of Phase 2 meeting, including whether the proposed pivotal program will support registration of lorundrostat which is a review issue with the FDA upon submission of an NDA; our dependence on third parties in connection with manufacturing, research and clinical and nonclinical testing; unexpected adverse side effects or inadequate efficacy of lorundrostat that may limit its development, regulatory approval and/or commercialization; unfavorable results from clinical trials and nonclinical studies; results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results; our ability to maintain undisrupted business operations due to any pandemic or future public health concerns; regulatory developments in the United States and foreign countries; our reliance on our exclusive license with Mitsubishi Tanabe Pharma to provide us with intellectual property rights to develop and commercialize lorundrostat; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading Risk Factors in our annual report on Form 10-K, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact: Investor Relations investorrelations@mineralystx.com
Media Relations Tom Weible Elixir Health Public Relations Phone: (1) 515-707-9678 Email:tweible@elixirhealthpr.com
Read the original here:
Mineralys Therapeutics Announces First Subject Dosed in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the ... - GlobeNewswire
- Hypertension: Practice Essentials, Background, Pathophysiology - Medscape Reference - April 10th, 2018 [April 10th, 2018]
- High blood pressure (hypertension) - Symptoms and causes ... - May 18th, 2018 [May 18th, 2018]
- 10 Causes of Hypertension - A Diet High In Salt Content - June 21st, 2018 [June 21st, 2018]
- Homeopathy Hypertension Remedies | High Blood Pressure ... - July 5th, 2018 [July 5th, 2018]
- European Society of Hypertension - July 7th, 2018 [July 7th, 2018]
- List of High Blood Pressure (Hypertension) Medications (259 ... - July 26th, 2018 [July 26th, 2018]
- Hypertension (High Blood Pressure) Charts, Symptoms, Diet ... - September 2nd, 2018 [September 2nd, 2018]
- Vitamin D and hypertension - September 8th, 2018 [September 8th, 2018]
- 2014 Guideline for Management of High Blood Pressure - September 29th, 2018 [September 29th, 2018]
- Essential hypertension - Wikipedia - September 30th, 2018 [September 30th, 2018]
- Hypertension Treatment & Drugs | Hypertension Causes ... - September 30th, 2018 [September 30th, 2018]
- Hypertension (High Blood Pressure) - October 13th, 2018 [October 13th, 2018]
- Hypotension - Wikipedia - October 30th, 2018 [October 30th, 2018]
- Hypertension | pathology | Britannica.com - October 30th, 2018 [October 30th, 2018]
- Hypertension | Cornell University College of Veterinary Medicine - November 10th, 2018 [November 10th, 2018]
- 2014 Guideline for Management of High Blood Pressure - JAMA - November 18th, 2018 [November 18th, 2018]
- Pharmacologic Treatment of Hypertension in Adults | Annals ... - November 18th, 2018 [November 18th, 2018]
- 10 Causes of Hypertension - High In Salt Consumption - November 29th, 2018 [November 29th, 2018]
- High blood pressure (hypertension) - Diagnosis and treatment ... - November 29th, 2018 [November 29th, 2018]
- High Blood Pressure Symptoms - Hypertension Symptoms - December 9th, 2018 [December 9th, 2018]
- Hypertension - Medscape Reference - December 21st, 2018 [December 21st, 2018]
- Hypertension - Lab Tests Online - December 21st, 2018 [December 21st, 2018]
- High Blood Pressure (Hypertension): Symptoms ... - OnHealth - December 21st, 2018 [December 21st, 2018]
- High Blood Pressure | Hypertension | MedlinePlus - December 27th, 2018 [December 27th, 2018]
- Hypertension - Wikipedia - December 27th, 2018 [December 27th, 2018]
- Hypertension: Causes and Risk Factors - verywellhealth.com - January 1st, 2019 [January 1st, 2019]
- Hypertension - Genetics Home Reference - NIH - January 20th, 2019 [January 20th, 2019]
- Hypertension: Nursing Care Management and Study Guide - April 7th, 2019 [April 7th, 2019]
- High blood pressure (hypertension) Disease Reference Guide ... - April 7th, 2019 [April 7th, 2019]
- Pulmonary hypertension - Symptoms and causes - Mayo Clinic - September 14th, 2019 [September 14th, 2019]
- Incident Hypertension Associated With Continuous NSAID Use in Ankylosing Spondylitis - Rheumatology Advisor - October 12th, 2019 [October 12th, 2019]
- The innovative new ways scientists are tackling high blood pressure - Noted - October 12th, 2019 [October 12th, 2019]
- If You Have High Blood Pressure, You May Be at Higher Risk for This Cancer - msnNOW - October 12th, 2019 [October 12th, 2019]
- MODERATO II Study: Cardiac Neuromodulation Significantly Reduces Systolic Blood Pressure - Diagnostic and Interventional Cardiology - October 12th, 2019 [October 12th, 2019]
- Kidney-heart connection is focus of upcoming HealthyLife seminar - Times Union - October 12th, 2019 [October 12th, 2019]
- High blood pressure: Six foods proven to lower your reading - Express - October 14th, 2019 [October 14th, 2019]
- Sepetaprost Effective and Safe in Glaucoma, Ocular Hypertension - Monthly Prescribing Reference - October 14th, 2019 [October 14th, 2019]
- India, Stressed: More than Half of Commuters in Metro Cities Likely to Commit Road Rage - News18 - October 17th, 2019 [October 17th, 2019]
- University College London Awarded 1M to Advance Heart, PH Research Using Computational Biology - Pulmonary Hypertension News - October 17th, 2019 [October 17th, 2019]
- One in 10 children on the verge of heart attack risk - The New Daily - October 17th, 2019 [October 17th, 2019]
- Healthy living: Salt and hypertension - Forbes India - October 17th, 2019 [October 17th, 2019]
- The global blood pressure (BP) monitoring devices market size is expected to reach USD 2.47 billion by 2026 - GlobeNewswire - October 17th, 2019 [October 17th, 2019]
- Vitamin D Deficiency And Hypertension: Is There A Relation Between Low Levels Of Vitamin D And High Blood Pressure? - NDTV News - October 17th, 2019 [October 17th, 2019]
- Hypertension in Indians - Forbes India - October 17th, 2019 [October 17th, 2019]
- Health: Worrying rise of hypertension in Indians - Forbes India - October 17th, 2019 [October 17th, 2019]
- More than 1100 health care organizations earn BP-control honor - American Medical Association - October 17th, 2019 [October 17th, 2019]
- Medication Adherence In Patients With Arterial Hypertension: The Relat | PPA - Dove Medical Press - October 17th, 2019 [October 17th, 2019]
- High levels of stress increase hypertension risk in black individuals - Healio - October 17th, 2019 [October 17th, 2019]
- Dapagliflozin Receives FDA Approval for Reducing Heart Failure Hospitalization Risk - Endocrinology Advisor - October 23rd, 2019 [October 23rd, 2019]
- Death of Clay County inmate prompts change in housing for inmates with specific medical needs - FirstCoastNews.com WTLV-WJXX - October 23rd, 2019 [October 23rd, 2019]
- New OPSUMIT (macitentan) Data Show Initial Combination Therapy with Tadalafil Improved Hemodynamic Clinical and Functional Parameters in Patients with... - October 23rd, 2019 [October 23rd, 2019]
- High Blood Pressure: Why salt is considered a harbinger of hypertension? - PINKVILLA - October 23rd, 2019 [October 23rd, 2019]
- Chronic Stress in African-Americans Linked to Hypertension - TCTMD - October 23rd, 2019 [October 23rd, 2019]
- Why all the fuss around hypertension? - Firstpost - October 23rd, 2019 [October 23rd, 2019]
- Study explores why Caribbean adults have higher hypertension rates - Yale News - October 23rd, 2019 [October 23rd, 2019]
- Hypertension in adults: summary of updated NICE guidance - The BMJ - October 23rd, 2019 [October 23rd, 2019]
- Diabetes, blood pressure and cancer cases are rising rapidly in India - Times of India - November 2nd, 2019 [November 2nd, 2019]
- Is there a link between breastfeeding and diabetes - Medical News Bulletin - November 2nd, 2019 [November 2nd, 2019]
- High Blood Pressure: Lower hypertension by eating less of these food groups - PINKVILLA - November 2nd, 2019 [November 2nd, 2019]
- Chronic high blood pressure in pregnant women on the rise - MahoningMatters.com - November 2nd, 2019 [November 2nd, 2019]
- Unhealthy Lifestyle and Indian Ethnicity Tied to Hypertension - Forbes India - November 2nd, 2019 [November 2nd, 2019]
- Cardio Round-up: Walkability and CVD; Pollution and Stroke; and More - DocWire News - November 2nd, 2019 [November 2nd, 2019]
- Hypertension Tied to Over One-Third of Population-Attributable CVD Risk in U.S. Black Adults - DocWire News - November 2nd, 2019 [November 2nd, 2019]
- This Is What Makes Oats Idli An Ideal Breakfast For A High Blood Pressure Diet - NDTV Food - November 11th, 2019 [November 11th, 2019]
- Global Idiopathic Intracranial Hypertension Therapeutics Market 2019-2023 | Evolving Opportunities with AbbVie Inc. and Astellas Pharma Inc. |... - November 11th, 2019 [November 11th, 2019]
- Severe Hypertension Common in aHUS Patients and Soliris Effective at Treating Them, Study Finds - aHUS News - November 11th, 2019 [November 11th, 2019]
- Overhydration Is a Risk Factor for Post-Dialysis Hypertension - Renal and Urology News - November 11th, 2019 [November 11th, 2019]
- In AS, Hypertension Risk Linked to Continuous NSAID Use, Study Says - Ankylosing Spondylitis News - November 11th, 2019 [November 11th, 2019]
- Physicians, Patient Discuss Intentional Nonadherence in Hypertension Therapy - AJMC.com Managed Markets Network - November 11th, 2019 [November 11th, 2019]
- More than 50,000 suffer from diabetes, nearly a lakh from hypertension - The Indian Express - November 14th, 2019 [November 14th, 2019]
- Cause of John Witherspoons untimely death revealed - TheGrio - November 14th, 2019 [November 14th, 2019]
- This Hyderabad-based Start-up is Helping Corporates Improve the Health of their Employees - Entrepreneur - November 14th, 2019 [November 14th, 2019]
- ER visits jumped after valsartan blood pressure medication recall, study says - CBC.ca - November 14th, 2019 [November 14th, 2019]
- The ALK-1/SMAD/ATOH8 axis attenuates hypoxic responses and protects against the development of pulmonary arterial hypertension - Science - November 14th, 2019 [November 14th, 2019]
- Health screenings given to raise awareness at West Philly barbershop - The Philadelphia Tribune - November 14th, 2019 [November 14th, 2019]
- Blood pressure monitoring must be a part of a diabetic's routine - Gulf News - November 14th, 2019 [November 14th, 2019]
- Early Warning Signs of CKD Going Unnoticed in Veterans, Especially Those With Hypertension - AJMC.com Managed Markets Network - November 14th, 2019 [November 14th, 2019]
- The Epidemic of Hypertension and Vulnerability of Indians - Forbes India - November 14th, 2019 [November 14th, 2019]
- Knowing the facts: Hypertension vis-a-vis Lifestyle - Forbes India - November 14th, 2019 [November 14th, 2019]
- Heart hormones that affect development of diabetes, hypertension differ in African Americans and whites - UAB News - November 14th, 2019 [November 14th, 2019]